GCM
ENTA icon

Gladius Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Gladius Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,620
Closed -$34K – 310
2024
Q2 		$34K Sell
2,620
-171
-6% -$2.31K ﹤0.01% 195
2024
Q1 		$48.7K Buy
+2,791
New +$36.9K 0.02% 177

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gladius Capital Management's ENTA Position: Q3 2024 in Review

Gladius Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2024, closing a stake of 2,620 shares — an estimated $34K sold.

Gladius Capital Management first reported a position in ENTA in Q1 2024 and held it in 2 quarters. The position peaked at $48.7K in Q1 2024. 111 funds tracked by Wall St. Rank hold ENTA as of Q3 2024.

  • Gladius Capital Management reported no remaining Enanta Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Gladius Capital Management sold 2,620 Enanta Pharmaceuticals shares in Q3 2024, an estimated $34K.
  • Gladius Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Gladius Capital Management's Enanta Pharmaceuticals position peaked at $48.7K in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2024.

Based on Gladius Capital Management's 13F filing for Q3 2024, filed 6 Nov 2024.